Use of transjugular intrahepatic portosystemic shunt in liver disease
|
|
- Gladys Horton
- 5 years ago
- Views:
Transcription
1 Vol. XVIII No. 3 JOURNAL OF VASCULAR NURSING PAGE 83 Use of transjugular intrahepatic portosystemic shunt in liver disease Patricia Ann Radovich, RN, MSN, CCRN, FCCM Persons with cirrhosis have many complications. Two of these complications are refractory ascites and recurrent gastrointestinal hemorrhage. When medical management has proved ineffective in the management of these two complications, a transjugular intrahepatic portosystemic shunt can be a treatment option. This outpatient procedure can reduce ascites, minimize the need for diuretics, and reduce the potential for gastrointestinal hemorrhage. The procedure is associated with the development of hepatic encephalopathy, which requires vigilant nursing observation. Education of the patient and family regarding the potential development of encephalopathy and the need for follow-up by the physician is important. The collaboration of physicians and nurses in the ongoing monitoring and follow-up of these patients can contribute to an improved quality of life and reduced hospitalizations. Nurses play an important role in alerting physicians to changes in patient condition that might indicate a narrowing of the transjugular intrahepatic portosystemic shunt, which requires intervention. (J Vasc Nurs 2000;18:83-7) Persons with a diagnosis of cirrhosis can be asymptomatic for many years. They eventually become symptomatic and complications may develop. These complications include the development of ascites, portal hypertension with esophageal varices, jaundice, and encephalopathy. The esophageal varices and refractory ascites are the focus of this article. MEDICAL MANAGEMENT OF ESOPHAGEAL VARICIES Esophageal varices are diagnosed during an esophagogastroduodenoscopy or when upper gastrointestinal bleeding develops in the patient resulting in hospitalization and transfusion. Esophageal varices develop when the pressure in the portal system increases and causes dilatation of the esophageal veins. This complication of cirrhosis is associated with significant morbidity and mortality. The usual medical management to reduce or eliminate esophageal varices involves frequent endoscopies with either Patricia Ann Radovich, RN, MSN, CCRN, FCCM, is a clinical nurse specialist hepatology, Loma Linda University Medical Center, Loma Linda, California. Address reprint requests to Patricia Ann Radovich, RN, MSN, CCRN, FCCM, Loma Linda University Medical Center, Anderson St, Room 1405, Loma Linda, CA Copyright 2000 by the Society for Vascular Nursing, Inc /2000/$ /1/ doi: /mvn CASE 1 Mr C is a 49-year-old Hispanic man who had a TIPS placed for variceal hemorrhage in Since that time, he has had multiple revisions of his TIPS because of decreased velocity on Doppler ultrasonography. In January 1999, the ultrasonography revealed that flow in the caval end of the TIPS was 50 cm per second (normal flow = >50 cm per second). The pressure gradient at the end of the stent at that time was 15 mm Hg. A balloon dilatation was performed with the pressure gradient measurement reduced to 9-11 mm Hg. In September 1999, an upper gastroduodenoscopy was performed, which revealed grade 3 esophageal varices. The patient was symptomatic with an increase in ascitic fluid and increased lethargy. Throughout the course of his treatment, the patient had been on lactulose for chronic encephalopathy. Although TIPS was thought to be the treatment of choice for the reduction of portal hypertension, the development of hepatic encephalopathy and the need for frequent stent revisions have many physicians choosing surgical portosystemic shunts in patients who are Child s class A and who are not candidates for liver transplantation. In candidates for liver transplantation, TIPS is preferred. esophageal ligation (banding) or injection sclerotherapy as well as pharmacologic management with the use of β-blockers for reduction of portal pressure. In severe instances, balloon tamponade may be necessary. In spite of aggressive medical management, some patients with portal hypertension are refractory to treatment of their esophageal varices. In patients with recurrent variceal hemorrhage in spite of adequate medical and endoscopic treatment, a transjugular intrahepatic portosystemic shunt (TIPS) has been used to reduce the portal hypertension seen in cirrhosis (Case 1). MANAGEMENT OF ASCITES Ascites is the development of serous fluid in the intraabdominal cavity. It is a complication of liver disease. Persons in whom ascites develops are treated with a low-sodium diet (2 g sodium) and diuretic therapy. The diuretics used are spironolactone and furosemide, which are adjusted to a maximum of 400 mg of spironolactone and 180 mg of furosemide. 1 Diuretic adjustments are made on the basis of a person s weight gain or loss, renal function, dietary compliance, and frequency of abdominal paracentesis. When a patient has
2 PAGE 84 JOURNAL OF VASCULAR NURSING SEPTEMBER 2000 CASE 2 Figure 1. Interventional radiology film: Transjugular intrahepatic stent. Mr Y is a 51-year-old white man with cirrhosis secondary to alcoholic liver disease. Ascites developed and had become refractory during the last 4 months. His renal function was becoming impaired with a rising serum creatinine of 2.3. He was requiring large volume paracentesis (8-10 L) every 2 weeks. He was on spironolactone 100 mg (this had been reduced from 300 mg every morning because of his renal insufficiency) and furosemide 40 mg (which had been reduced from 120 mg every morning because of the renal insufficiency). He was following a 2-gm sodium diet with good compliance. His Child/Pugh score is 8 with a Child s class B. His laboratory values were sodium (Na) 136 mmol/l; potassium (K) 4.3 mmol/l; serum urea nitrogen (BUN) 36 mg/dl; creatinine (C) 2.3 mg/dl; albumin 2.8; total bilirubin (T bili) 0.4 mg/dl; alkaline phosphatase (ALK-P) 87 U/L; aspartate aminotransferase (AST) 27 U/L; alanine aminotransferase (ALT) 18 U/L; prothrombin time (PT) 16.4 sec; international normalized ratio (INR) TIPS PROCEDURE TIPS is an interventional radiologic procedure performed in many medical centers in the United States and internationally. A TIPS is a shunt created via a right transjugular approach and uses the normal liver vascular anatomy for an intrahepatic (parenchymal) tract between the intrahepatic portion of the portal vein and the hepatic veins. The right hepatic vein is usually used because of its large size. Before stent placement, pressure measurements are obtained from the portal vein and inferior vena cava to document the baseline portacaval gradient. A portacaval gradient of less than 12 mm Hg is considered acceptable. The tract is then reinforced with a metallic stent. The diameter of the stent is 8 mm to 10 mm depending on the reduction in portal pressures. The stent placement within this shunt will decompress the portal system (Figures 1 and 2). 2-4 Figure 2. Interventional radiology film: TIPS with a gradient of 15 mm Hg. reached the maximum dose of diuretics or when renal insufficiency develops requiring a reduction in diuretics and is requiring frequent large volume paracentesis (at least monthly but usually every 2 weeks), he or she is considered to have refractory ascites. 1 At this point, a TIPS is considered to relieve the debilitating condition (Case 2). CONTRAINDICATIONS Contraindications for placement of TIPS are divided into absolute contraindications, which include right-sided heart failure with elevated central venous pressure, polycystic liver, and severe hepatic failure. TIPS is also contraindicated in patients with known severe anaphylactoid reactions to contrast media. Placement of a TIPS in the setting of right-sided heart failure exacerbates the portal hypertension and increases the risk of variceal hemorrhage. In addition, TIPS has sometimes exacerbated right-sided heart failure. The use of TIPS in patients with polycystic liver disease has the risk of puncturing a hepatic cyst, resulting in hemorrhage. In severe hepatic failure, the use of TIPS could result in further compromise of hepatic function. Once the absolute contraindications have been eliminated, the physician will review the relative contraindications to placement of a TIPS. These contraindications include active intrahepatic or systemic infection, severe hepatic encephalopathy, and portal vein thrombosis. 3,5 ADVERSE EFFECTS Adverse effects of TIPS placement include procedural complications associated with any vascular procedure requiring con-
3 Vol. XVIII No. 3 JOURNAL OF VASCULAR NURSING PAGE 85 TABLE I. ADVERSE EFFECTS OF TIPS PLACEMENT Procedural complications Local puncture site hematoma Pain Puncture of other abdominal organs Dysrhythmias Hypotension Migration of stent Hemolytic anemia Fever Reaction to contrast agents Spontaneous thrombosis of TIPS Life-threatening complications Hemoperitoneum Hemobilia Acute hepatic ischemia Cardiac puncture Pulmonary edema Septicemia Chronic complications Portal or splenic vein thrombosis 1%-15% 2 Chronic hemolysis 1%-3% 2 Worsening of hepatic function 1%-5% 2 Shunt stenosis 33%-66% 2 Hepatic encephalopathy 15%-30% 2 trast media. Many of these events appear to be related to the experience of the person performing the procedure and range from site hematoma and nephrotoxicity from contrast media to more significant reactions including anaphylaxis secondary to contrast dye allergy. Severe life-threatening complications such as acute hepatic ischemia and pulmonary edema occur in 1% to 2% of the patients. Chronic complications, which appear to be the most frequently seen, include hepatic encephalopathy and TIPS dysfunction (Table I). 3,4 TIPS DYSFUNCTION Recent studies have found that the portacaval pressure gradient is significantly decreased after the TIPS procedure. The pressures have been decreased from 17.7 mm Hg to 8.6 mm Hg. If the pressure gradient increases to a mean pressure of 18 mm Hg, rebleeding occurs. This value is usually a pressure that was close to the mean portal pressure gradient before stent placement. In a study 1 year after TIPS placement, 77% of the patients underwent balloon angioplasty or restenting. In this same population, 80% again were found to have a portacaval pressure gradient of Figure 3. Interventional radiology film: TIPS after dilatation with a gradient of 9-11 mm Hg. greater than 12 mm Hg 1 year after reintervention. 6 TIPS dysfunction consists of a progressive stenosis rather than complete occlusion. Neointimal proliferation and development of fibrosis within the parenchymal tract occur, which gradually narrows the stent. The time of highest risk for occlusion is 6 to 12 months after placement. TIPS monitoring for patency is done by ultrasonography, initially within 1 month of placement, then every 3 months, progressing to every 6 months after the first year (Case 1). 7 HEPATIC ENCEPHALOPATHY After portal decompression with TIPS placement, an associated increased risk of the development of hepatic encephalopathy has occurred. 6 Rates of hepatic encephalopathy range from 25% to 30% after TIPS placement. In some patients, this is a new onset; whereas in a small number of patients, it is exacerbation of a current problem. Hepatic encephalopathy usually occurs within the first 3 months after stent placement. Although hepatic encephalopathy can be treated with medications, in a significant number of patients studied, the encephalopathy interfered with activities of daily living. In some severe cases (as high as 10%), the client was not responsive to treatment and required hospitalization. 3,8,9 Studies have identified predictive factors such as prior history of hepatic encephalopathy, nonalcoholic liver disease, age greater than 60 years, and portal systemic gradient of less than 12 mm Hg. A portal systemic gradient of less than 12 mm Hg is at decreased risk for rebleeding but has been associated with an increased risk of hepatic encephalopathy. SURGICAL SHUNTS It has been suggested that patients with good liver function should be candidates for surgical shunts in light of the long-term
4 PAGE 86 JOURNAL OF VASCULAR NURSING SEPTEMBER 2000 TABLE II. HEPATIC ENCEPHALOPATHY Subclinical encephalopathy Normal level of consciousness Normal intellect and personality Abnormal psychometric analysis Grade I encephalopathy Inverted sleep pattern, restlessness Forgetfulness, mild confusion, agitation, irritability Tremor, apraxia, incoordination, impaired handwriting Grade II encephalopathy Lethargy, slow responses Disorientation, amnesia, decreased inhibitions, inappropriate behavior Asterixis, dysarthria, ataxia, hypoactive reflexes Grade III encephalopathy Somnolence but arousability, confusion Disorientation, aggressive behavior Asterixis, hyperactive reflexes, Babinski s signs, muscle rigidity Grade IV encephalopathy Coma Decerebration patency, decreased rate of rebleeding, and decreased development of hepatic encephalopathy. The 7-year patency rate is 95% and the percentage of rebleeding is 8%. Many recent studies comparing complications, cost, and survival now indicate that use of a TIPS in patients with Child s class A cirrhosis is not warranted. 10,11 In fact, surgical shunts in these patients have been determined to be more cost effective than placement of a TIPS. Instead, TIPS should be used in patients with Child s class B cirrhosis who are candidates for liver transplantation. LIVER TRANSPLANTATION In patients who may undergo liver transplantation at a future date, it is important that the TIPS not compromise the surgical procedure. The stent should not extend into the suprahepatic cava because the recipient liver is transected at the level of the suprahepatic cava. It should not extend into the main portal vein because thrombosis can occur. 4 In patients who have undergone a portacaval H-graft shunt rather than a TIPS, there are associated intraoperative complications such as increased blood loss and coagulopathy. It has also been shown that the postoperative complication rate was higher for patients with primary nonfunction, re-exploration of intraperitoneal bleeding, and hematomas. 5 TABLE III. PATIENT AND CAREGIVER EDUCATION Procedure/presedation Risk for hepatic encephalopathy Signs and symptoms of hepatic encephalopathy Need for ultrasonography follow-up Need for revisions Signs and symptoms of stent stenosis Emergency procedures for variceal bleeding NURSING IMPLICATIONS The placement of a TIPS is usually an outpatient procedure unless the patient has been hospitalized for gastrointestinal hemorrhage. The care of the patient after the procedure involves ensuring recovery from the conscious sedation and monitoring of the patient s vital signs and airway. The immediate postprocedure concern is monitoring the insertion site for signs and symptoms of infection, hematoma formation, pain, or fever. If the patient is hospitalized, the nurse should monitor the patient for signs and symptoms of hepatic encephalopathy, elevation in liver tests, and postprocedure complications. Patients with cirrhosis who are going to undergo a TIPS and their caregivers should be aware of the potential for stenosis of the stent and development of hepatic encephalopathy (Table III). Nursing staff should review the signs and symptoms of hepatic encephalopathy (Table II) with both the patient and his or her caregiver. If hepatic encephalopathy develops in the patient after the procedure, medications for control of encephalopathy should be reviewed. Protein restriction is avoided unless medical management of the hepatic encephalopathy fails. The current method for identifying subclinical and clinical encephalopathy is by use of a number connection test called a Trail Test. 12 Ammonia levels have been found to poorly correlate with the grade of hepatic encephalopathy, and this measurement is of little value in the diagnosis of hepatic encephalopathy. 13 Nurses should be trained in the use of these number connection tests so that they may more accurately gage their patient s level of encephalopathy. Patients should also be instructed regarding the need for frequent ultrasonography and the importance of keeping these appointments so that the condition of the stent can be continuously monitored. In this way, a change in the blood flow through the stent can be observed before the development of rebleeding. Emergency instructions should be reviewed with the patient and caregiver in case rebleeding does occur. CONCLUSION The use of TIPS in the patient with cirrhosis with refractory gastrointestinal hemorrhage or ascites continues to be studied. It
5 Vol. XVIII No. 3 JOURNAL OF VASCULAR NURSING PAGE 87 has proven effective in reducing the life-threatening hemorrhages in patients with cirrhosis and in improving the quality of life for patients with refractory ascites. It is only with ongoing attentive observation and thorough patient education by nursing staff that clinical changes are detected early. However, the need for vigilant monitoring by nurses and physicians to detect the development of hepatic encephalopathy and the frequency of stent stenosis means that we must continue to look for more sustained, cost-effective therapy in this population. REFERENCES 1. Somberg KA, Lake JR, Tomlanovich SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995;21: Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997;112: Shiffman ML, Jeffers L, Hoofnagle JH, et al. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Disease Advisory Board. Hepatology 1995;22: Kamath PS, McKusick MA. Transvenous intrahepatic portosystemic shunts. Gastroenterology 1996;111: Busitill RW, Klintmalm G. Transplantation of the liver. Philadelphia: WB Saunders; p Casado M, Bosch J, Carcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: Saxon RR, Ross PL, Mendel-Hartvig J, et al. Transjugular intrahepatic portosystemic shunt patency and the importance of stenosis location in the development of recurrent symptoms. Radiology 1998;207: Rössle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330: Coldwell DM, Ring EJ, Rees CR, et al. Multicenter investigation of the portal hypertension. Radiology 1969;20: Rosemurgy AS, Goode SE, Zwiebel BR, et al. A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small diameter prosthetic h-graft portacaval shunts in the treatment of bleeding varices. Ann Surg 1996;224: Collins JC, Ong MJ, Rypins EB, et al. Partial portacaval shunt for variceal hemorrhage: longitudinal analysis of effectiveness. Arch Surg 1998;133: Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-Lasparate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28: Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337: RECOMMENDED READING Hausegger KA, Sternthal HM, Glein GE, et al. Transjugular intrahepatic portosystemic shunt: angiographic follow-up and secondary interventions. Radiology 1994;191: Darling RC III, Shah DM, Change BB, et al. Long term follow up of poor risk patients under going small diameter portacaval shunts. Am J Surg 1992;164: Capussotti L, Vergara V, Polastri R, et al. A critical appraisal of the small diameter portacaval H-graft. Am J Surg 1995;170: Shaked A, Busuttil R. Liver transplantation in patients with portal vein thrombosis and central portacaval shunts. Ann Surg 1991;214: Zakim D, Boyer TD. Hepatology: a textbook of liver disease. Vol 1. Philadelphia: WB Saunders; p. 735.
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationMichele Bettinelli RN CCRN Lahey Health and Medical Center
Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationTransjugular Intrahepatic Portosystemic Shunt Reduction for Management of Recurrent Hepatic Encephalopathy
CLINICAL IMAGES Ochsner Journal 17:311 316, 2017 Ó Academic Division of Ochsner Clinic Foundation Transjugular Intrahepatic Portosystemic Shunt Reduction for Management of Recurrent Hepatic Encephalopathy
More informationTranjugular Intrahepatic Portosystemic Shunt
Tranjugular Intrahepatic Portosystemic Shunt Christopher Selhorst July 25, 2005 BIDMC Radiology Overview Portal Hypertension Indications, Contraindications The Procedure Case Review Complications Outcomes
More informationAASLD PRACTICE GUIDELINE. The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension. Preamble.
AASLD PRACTICE GUIDELINE The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension Thomas D. Boyer 1 and Ziv J. Haskal 2 Preamble The recommendations in this article
More informationVARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.
VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationTransjugular Intrahepatic
Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Clinical and Procedural Review Mark R. Werley, M.D. and John Briguglio, M.D. Lancaster Radiology Associates, Ltd. INTRODUCTION This article reviews
More informationfollowing the last documented transfusion; thereafter, evaluate the residual impairment(s).
Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood
More informationBarbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana
STROKOVNI SESTANEK ZDRUŽENJA HEMATOLOGOV SLOVENIJE IN ZDRUŽENJA ZA TRANSFUZIJSKO MEDICINO, Terme Zreče, 17.-18.4.2015 Barbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana goals,
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationPORTAL HYPERTENSION. Tianjin Medical University LIU JIAN
PORTAL HYPERTENSION Tianjin Medical University LIU JIAN DEFINITION Portal hypertension is present if portal venous pressure exceeds 10mmHg (1.3kPa). Normal portal venous pressure is 5 10mmHg (0.7 1.3kPa),
More informationManagement of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationCHAPTER 1. Alcoholic Liver Disease
CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end
More informationRisk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis
Original Article Page 1 of 9 Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Rui Sun*, Xingshun Qi* #, Deli Zou, Xiaodong Shao, Hongyu Li, Xiaozhong
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationLIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationTitle: Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication
Title: Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication Authors: Alejandro Salagre García, Carolina Muñoz Codoceo, Elena Gómez Domínguez, Inmaculada
More informationVariceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationBRTO /PARTO Indications and outcomes
BRTO /PARTO Indications and outcomes Saher Sabri, MD Associate Professor of Radiology and Surgery Division of Interventional Radiology University of Virginia Health System Saher Sabri, M.D. Speakers Bureau:
More informationTransjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding in Patients with Viral Liver Cirrhosis: Predictors of Early Mortality
Early Mortality with TIPS for Variceal Bleeding Interventional Radiology Original Research Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding in Patients with Viral Liver Cirrhosis:
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute variceal bleeding management of, 251 262 balloon tamponade of esophagus in, 257 258 endoscopic therapies in, 255 257. See also Endoscopy,
More informationNYU School of Medicine Department of Radiology Rotation-Specific House Staff Evaluation
Vascular & Interventional Radiology Rotation 1 Core competency in vascular and interventional radiology during the first resident rotation consists of clinical objectives, technical objectives and image
More informationCHAPTER 7. End Stage Liver Disease in the ICU: Walking a Tightrope. Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing
CHAPTER 7 End Stage Liver Disease in the ICU: Walking a Tightrope Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing Besey Oren, Assistant Professor Istanbul University Health
More informationPORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications
PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications Edy G. Trujillo, RN, MSN, ACNP-BC Liver Transplant RRUCLA Medical Center July 31, 2018 What Do We All Look Forward
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationEtiology of liver cirrhosis
Liver cirrhosis 1 Liver cirrhosis Liver cirrhosis is the progressive replacement of normal hepatic cells by fibrous scar tissue, This scarring is accompanied by the loss of viable hepatocytes, which are
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationComplications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
More informationPortogram shows opacification of gastroesophageal varices.
Portogram shows opacification of gastroesophageal varices. http://clinicalgate.com/radiologic-hepatobiliary-interventions/ courtesyhttp://emedicine.medscape.com/article/372708-overview DR.Thulfiqar Baiae
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationThe Leeds Teaching Hospitals NHS Trust Transjugular Intrahepatic Portosystemic Shunt (TIPS)
n The Leeds Teaching Hospitals NHS Trust Transjugular Intrahepatic Portosystemic Shunt (TIPS) Information for patients Your liver doctor has recommended that you have a Transjugular Intrahepatic Portosystemic
More informationQuality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Cardiovasc Intervent Radiol (2012) 35:1295 1300 DOI 10.1007/s00270-012-0493-y CIRSE STANDARDS OF PRACTICE GUIDELINES Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS)
More informationManagement of Hepatic Encephalopathy
Management of Hepatic Encephalopathy Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationTransjugular Intrahepatic Portosystemic Shunt (TIPS) About your procedure
Patient Education Transjugular Intrahepatic Portosystemic Shunt (TIPS) About your procedure This handout explains what a transjugular intrahepatic portosystemic shunt is and what to expect when you have
More informationNursing Care & Management of the Pre-Liver Transplant Population. Christine Kiamzon, RN, MSN, PCCN 8 North Educator
Nursing Care & Management of the Pre-Liver Transplant Population Christine Kiamzon, RN, MSN, PCCN 8 North Educator Objectives 1. Identify key nursing interventions in caring for pre-transplant ESLD patients.
More informationNursing Care & Management of the Pre-Liver Transplant Population
Nursing Care & Management of the Pre-Liver Transplant Population Christine Kiamzon, RN, MSN, PCCN 8 North Educator Objectives 1. Identify key nursing interventions in caring for pre-transplant ESLD patients.
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationFactors Predicting Survival after Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years Experience from a Single Tertiary Medical Center
Factors Predicting Survival after Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years Experience from a Single Tertiary Medical Center Jen-Jung Pan, MD, PhD, Chaoru Chen, PhD, James G. Caridi,
More informationDRAFT. Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect. What is a transjugular intrahepatic portosystemic shunt?
UW MEDICINE PATIENT EDUCATION Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect This handout explains a transjugular intrahepatic portosystemic shunt and what to expect when
More informationPrimary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital Outline Natural history of esophageal varices Which
More informationDecompensated chronic liver disease
Decompensated chronic liver disease Definition of decompensated chronic liver disease Patients with chronic liver disease can present with acute decompensation due to various causes. The decompensation
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationDiagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
More informationRisk factors for stent graft thrombosis after transjugular intrahepatic portosystemic shunt creation
Original Article Risk factors for stent graft thrombosis after transjugular intrahepatic portosystemic shunt creation Younes Jahangiri, Timothy Kerrigan, Lei Li, Dominik Prosser, Anantnoor Brar, Johnathan
More informationUpdate in abdominal Surgery in cirrhotic patients
Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients
More informationCase Report INTRODUCTION CASE REPORT
Case Report J Korean Soc Transplant 2016;30:89-93 http://dx.doi.org/10.4285/jkstn.2016.30.2.89 Late Hepatic Venous Outflow Obstruction Following Inferior Vena Cava Stenting in Patient with Deceased Donor
More informationCase Report Inferior Vena Cava Torsion and Stenosis Complicated by Compressive Pericaval Regional Ascites following Orthotopic Liver Transplantation
Case Reports in Radiology Volume 2013, Article ID 576092, 4 pages http://dx.doi.org/10.1155/2013/576092 Case Report Inferior Vena Cava Torsion and Stenosis Complicated by Compressive Pericaval Regional
More informationSurgical Rescue of Surgical Failures
HPB Surgery, 1999, Vol. 11, pp. 151-155 Reprints available directly from the publisher Photocopying permitted by license only (C) 1999 OPA (Overseas Publishers Association) N.V. Published by license under
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationTransjugular intrahepatic portosystemic shunt (TIPS) Information for patients Sheffield Vascular Institute
Transjugular intrahepatic portosystemic shunt (TIPS) Information for patients Sheffield Vascular Institute You have been given this leaflet because you need a procedure called a transjugular intrahepatic
More informationDefinition: fibrosis and nodular regeneration resulting from hepatocellular injury
Cirrhosis Understanding the liver: Patterns of LFT Abnormalities - Hepatocellular/Transaminitis: o Ratio of AST: ALT >2:1 ETOH (keep in mind AST is also produced by red cells, heart muscle) o If Aminotransferases
More informationA COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING
A COMPARISON OF AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC ING IN PATIENTS WITH ASCITES MARTIN RÖSSLE, M.D., ANDREAS OCHS, M.D., VEIT GÜLBERG, M.D., VOLKER SIEGERSTETTER, M.D., JOSEPH HOLL, M.D., PETER
More informationEndovascular Techniques for Symptomatic Portal Hypertension. Michael Meuse, M.D. Vascular and Interventional Radiology
Endovascular Techniques for Symptomatic Portal Hypertension Michael Meuse, M.D. Vascular and Interventional Radiology Objectives Review indications and contraindications for TIPS Define a treatment algorithm
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationEvaluation of Clinical, Biochemical and Ultrasound Parameters in Diagnosis of Oesophageal Varices
Med. J. Cairo Univ., Vol. 78, No. 2, June: 105-109, 2010 www.medicaljournalofcairouniversity.com Evaluation of Clinical, Biochemical and Ultrasound Parameters in Diagnosis of Oesophageal Varices FAWZY
More informationPreliminary study of the permeability and safety of covered stents-grafts in pediatric TIPS
Preliminary study of the permeability and safety of covered stents-grafts in pediatric TIPS Poster No.: C-0354 Congress: ECR 2013 Type: Scientific Exhibit Authors: A. Bueno Palomino, L. Zurera Tendero,
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationHepatopulmonary Syndrome: An Update
Hepatopulmonary Syndrome: An Update Michael J. Krowka MD Professor of Medicine Division of Pulmonary and Critical Care Division of Gastroenterology and Hepatology Mayo Clinic Falk Liver Week October 11,
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationAcute TIPS occlusion due to iatrogenic arteriovenous shunt in a cirrhotic patient with total portal vein thrombosis
Interventional Medicine & Applied Science, Vol. 7 (4), pp. 166 170 (2015) CASE REPORT Acute TIPS occlusion due to iatrogenic arteriovenous shunt in a cirrhotic patient with total portal vein thrombosis
More informationHome Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia
Home Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia Hye Kyung Chang, Jung-Tak Oh, Seung Hoon Choi, Seok Joo Han Division of Pediatric Surgery, Department of Surgery, Yonsei
More informationACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 Appropriate Use Criteria. Indications A _ appropriate; I _ inappropriate; U _ uncertain
National Imaging Associates, Inc. Clinical guidelines ABDOMINAL, PELVIS, SCROTAL, RETROPERITONEAL ORGANS DUPLEX SCAN (US) CPT Codes: 93975 Bilateral or Complete 93976 - Unilateral or Limited Guideline
More informationV ariceal haemorrhage is a major cause of mortality and
270 LIVER DISEASE The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric : clinical and haemodynamic correlations D Tripathi, G Therapondos, E
More informationCase Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Thank you to Marika Rudler, Dominique Thabut, Adrian Gadano, and Jaime Bosch for
More informationThrombocytopenia and Chronic Liver Disease
Thrombocytopenia and Chronic Liver Disease Severe thrombocytopenia (platelet count
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationFollow this and additional works at:
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Comparison of transjugular intrahepatic portosystemic shunt with covered stent and balloon-occluded retrograde
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
More informationOverall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
More informationLIVER BIOPSY - THE FACTS. Abnormal liver function tests do suggest chronic disease, but there is no
LIVER BIOPSY - THE FACTS Source: Hepatitis C Foundation Handout Abnormal liver function tests do suggest chronic disease, but there is no correlation between liver function tests and the severity of the
More informationRisk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients
Oregon Health & Science University OHSU Digital Commons Scholar Archive 9-2014 Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients
More informationLeft-sided portal hypertension with a patent splenic vein: An impossible or a not-so-uncommon scenario?
Khan et al. 108 CASE REPORT PEER REVIEWED OPEN ACCESS Left-sided portal hypertension with a patent splenic vein: An impossible or a not-so-uncommon scenario? Iftikhar Khan, Ghassan Ramahi, Saif Zaabi,
More informationJMSCR Vol 04 Issue 08 Page August 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: http://dx.doi.org/10.18535/jmscr/v4i8.23 Portal Hypertension in Adults- A Comprehensive
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationDISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
More informationReview Article Role of Self-Expandable Metal Stents in Acute Variceal Bleeding
Hindawi Publishing Corporation International Journal of Hepatology Volume 2012, Article ID 418369, 6 pages doi:10.1155/2012/418369 Review Article Role of Self-Expandable Metal Stents in Acute Variceal
More informationWEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry
MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,
More informationThe Effect of Transjugular Intrahepatic Portosystemic Shunt on Platelet Counts in Patients With Liver Cirrhosis
The Effect of Transjugular Intrahepatic Portosystemic Shunt on Platelet Counts in Patients With Liver Cirrhosis Omar I. Massoud, MD, PhD, and Nizar N. Zein, MD Dr Massoud is an associate professor of medicine
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationAnaesthetic considerations and peri-operative risks in patients with liver disease
Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary
More informationCirrhosis Patient Teaching Information
Cirrhosis Patient Teaching Information CIRRHOSIS What is Cirrhosis: Cirrhosis is the end stages of a liver disease. Over time, from years to decades, fibrosis (or scar tissue) progresses through stages
More information